
    
      IBD patients in need of intensified adalimumab treatment will be randomized to receive 40mg
      sc weekly or 80mg sc every two weeks, and after 6 weeks of treatment each of the groups will
      be allocated to the other dosing regime. Adalimumab blood levels and other features such as
      specific drug antibodies and disease activity parameters will be compared between both
      groups.
    
  